logo-loader
viewGilead Sciences, Inc.

Anger as US snaps up supplies of Gilead coronavirus treatment Remdesivir

Developed economies have to go through the US pharma giant, which holds the patent.

Gilead Sciences, Inc. -
A long wait in Britain for Remdesivir potentially

Gilead Inc ((NASDAQ:GILD) has had almost all its global supplies of potential coronavirus treatment Remdesivir acquired by the US government.

The US Department of Health and Human Services (HSS) said it had bought more than 500,000 doses of the drug, which will mean Gilead sending the drug to the US for the next three months with people in the UK and rest of Europe not able to get supplies until October.

Remdesivir was developed to treat Ebola but trials recently have shown it to be effective in people with severe conditions resulting from coronavirus, cutting the time they spend in intensive care and reducing the virus’s ability to reproduce.

Dr Andrew Hill, a senior visiting research fellow at Liverpool University, told Sky News: "This deal that's been struck by America means that people with COVID-19 in the UK can't get access to these treatments that would get them out of hospital quickly and might improve their chances of survival.”

The investigational antiviral, which is temporarily approved in certain countries as coronavirus treatment, made the headlines on Monday after Gilead priced it at US$390 per vial, making a five-day course cost US$3,120.

Low-income countries can purchase a generic version after the Gilead inked licensing agreements with five manufacturers, but more developed economies have to go through the US pharma giant, which holds the patent.

Clinical trials showed that the antiviral can help patients with moderate pneumonia to recover faster compared to the standard of care over a 5-day course, while the 10-day treatment did not show statistical significance.

Last month, the cheaper and widely available steroid treatment dexamethasone was found to reduce death by up to one third in patients with severe COVID-19 symptoms.

Quick facts: Gilead Sciences, Inc.

Price: 68.17 USD

NASDAQ:GILD
Market: NASDAQ
Market Cap: $85.34 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Helix BioPharma extends Moffitt cancer center collaboration to further...

Helix BioPharma Corp (TSX:HBP) (OTCMKTS:HBPCF) CEO Heman Chao tells Proactive the immuno-oncology focused biotech has extended its collaboration with the Florida-based Moffitt Cancer Center for a further year, building on the pair's progress so far. Chao says Helix and Moffitt have already...

1 hour, 13 minutes ago

2 min read